...
首页> 外文期刊>American Journal of PharmTech Research >Inclusion of Diacerein with cyclodextrin carriers: Preparation, physicochemical characterization, cytotoxicity assessment and pharmacological evaluation
【24h】

Inclusion of Diacerein with cyclodextrin carriers: Preparation, physicochemical characterization, cytotoxicity assessment and pharmacological evaluation

机译:双醋瑞因与环糊精载体的结合:制备,理化性质,细胞毒性评估和药理学评估

获取原文

摘要

ABSTRACT The present investigation aims on the preparation and in-vitro/in-vivo examination of inclusion complex of Diacerein (DAR) an anthraquinone derivative indicated for treatment of osteoarthritis by inhibiting interlukin-1 and hydroxypropyl-β-cyclodextrin (HP-β-CD). In this study, the inclusion complexes of DAR with β-cyclodextrin (β-CD), HP-β-CD, methyl-β-cyclodextrin (M-β-CD) and γ-cyclodextrin (γ-CD) were prepared and characterized for phase solubility study and inclusion efficiency. On the basis of results obtained, HP-β-CD was selected to prepare inclusion complexes with DAR by physical mixing, kneading method and freeze drying method and subjected to solid state characterizations. Differential Scanning Calorimetry (DSC), X-ray Diffraction (XRD) and Infra-red spectroscopy (IR) analysis confirmed the formation of perfect inclusion complex of DAR with HP-β-CD in solids. In-vitro dissolution and % drug content of DAR in freeze dried inclusion complex showed its superiority over plain drug and commercial formulation. . In-vitro cell cytotoxicity studies (MTT Assay) using Caco-2 cell line model confirmed the bio-tolerability of DAR-inclusion complex. . The relative oral bioavailability of DAR in Albino rabbits resulted from Freeze dried inclusion complex was found 3.32 fold and 2.03 fold greater than plain DAR and marketed formulation, respectively which ultimately demonstrated the enhancement of oral bioavailability of DAR in freeze dried inclusion complex with HP-β-CD. Keywords: Inclusion complex, Diacerein, cyclodextrin, cytotoxicity, bioavailability
机译:摘要本研究旨在研究双醋瑞因(DAR)蒽醌衍生物包合物的制备及体外/体内检查,该蒽醌衍生物可通过抑制白介素-1和羟丙基-β-环糊精(HP-β-CD)来治疗骨关节炎。 )。本研究制备了DAR与β-环糊精(β-CD),HP-β-CD,甲基-β-环糊精(M-β-CD)和γ-环糊精(γ-CD)的包合物。用于相溶解度研究和包合效率。根据获得的结果,选择HP-β-CD通过物理混合,捏合法和冷冻干燥法制备具有DAR的包合物,并进行固态表征。差示扫描量热法(DSC),X射线衍射(XRD)和红外光谱(IR)分析证实了固体中DAR与HP-β-CD的完美包合物的形成。冻干包合复合物中DAR的体外溶出度和%药物含量显示出其优于纯药物和商业制剂的优势。 。使用Caco-2细胞系模型进行的体外细胞毒性研究(MTT分析)证实了DAR包合物的生物耐受性。 。冷冻干燥的包涵体复合物导致的DAR在白化家兔中的相对口服生物利用度分别比普通DAR和市售制剂高3.32倍和2.03倍,这最终证明DAR在HP-β冻干包合物中的口服生物利用度得到了增强-光盘。关键字:包合物,双醋瑞因,环糊精,细胞毒性,生物利用度

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号